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Heart failureAutophagy is a highly conserved degradation process by which intracellular components, including soluble
macromolecules (e.g. nucleic acids, proteins, carbohydrates, and lipids) and dysfunctional organelles (e.g. mito-
chondria, ribosomes, peroxisomes, and endoplasmic reticulum) are degraded by the lysosome. Autophagy is
orchestrated by the autophagy related protein (Atg) composed protein complexes to form autophagosomes,
which fuse with lysosomes to generate autolysosomes where the contents are degraded to provide energy for
cell survival in response to environmental and cellular stress. Autophagy is an important player in cardiovascular
disease development such as atherosclerosis, cardiac ischemia/reperfusion, cardiomyopathy, heart failure and
hypertension. Autophagy in particular contributes to cardiac ischemia, hypertension and diabetes by interaction
with reactive oxygen species generated in endoplasmic reticulum and mitochondria. This review highlights the
dual role of autophagy in cardiovascular disease development. Full recognition of autophagy as an adaptive or
maladaptive response would provide potential new strategies for cardiovascular disease prevention and man-
agement. This article is part of a Special Issue entitled: Autophagy and protein quality control in cardiometabolic
diseases.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Autophagy, ﬁrst coined by Belgian biochemist Christian de Duve in
1966 [1], is characterized by the lysosome-dependent degradation of
cytoplasm and damaged organelles such as mitochondria, endoplasmic
reticulum and peroxisomes, as well as eliminating intracellular path-
ogens. In addition, autophagy serves as a dynamic recycling system
to provide energy and building material for new protein and mem-
brane production to promote survival under conditions of starvation
[2]. Three types of autophagy have been deﬁned: macroautophagy,
microautophagy, and chaperone-mediated autophagy, each of whichonophosphate–activated protein
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Autophagy related protein (Atg) composed protein complexes coordi-
nate the formation of autophagosomes which fuse with lysosomes to
generate autolysosomes. The contents are then degraded, and the
breakdown products are released into the cytosol for synthetic and
metabolic pathways [2]. Autophagy has been linked to cardiovascular
diseases, as it is triggered by inﬂammation, hypoxia, oxidized lipopro-
tein, endoplasmic reticulum (ER) stress and reactive oxygen species
(ROS), which are involved in atherogenesis [3–5]. Autophagy also
promotes atherosclerotic plaque cell survival by degrading damaged
intracellular components and protecting cells from apoptosis [6]. How-
ever, excessive autophagy may cause cell death. The observation that
autophagy is activated during ischemia/reperfusion injury leads to the
hypothesis that autophagy is a critical regulator of ischemia/reperfusion
injury [7]. Indeed, autophagy promotes cell survival by eliminating
dysfunctional mitochondria, which may otherwise release ROS
leading to cell death [8]. Moreover, autophagy has diverse effects
on cardiomyopathy — whereas augmented autophagy ameliorates
dilated cardiomyopathy; autophagy activation promotes diabetic
cardiomyopathy [9–11]. Furthermore, autophagy may antagonize ven-
tricular hypertrophy by increasing protein degradation and decreasing
tissuemass. Thus, autophagy may be an adaptive response in heart fail-
ure [12]. Autophagy also protects the heart by maintaining contractile
function, as autophagosome dysfunction is associated with increased
apoptosis, mitochondrial injury, intracellular Ca2+ dysregulation and
cardiac dysfunction [13]. Lastly, autophagy mediates oxidative stress-
elicited myocardial injury in response to ischemia/reperfusion [14].
This review will address the above points in detail.
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Autophagy, literally “self-eating” in Greek, is the major intracellular
degradation system bywhich cellular components, including organelles
and protein aggregates, are delivered to and degraded in the lysosome
[2,15]. The purpose of autophagy is not limited to elimination of cell
cargo waste, but instead, autophagy serves as a dynamic recycling
system to provide energy and building material for new protein and
membrane production. Thus, autophagy helps maintain the health of
cells and tissues by replacing impaired cellular components with fresh
ones. In addition, it supplies endogenously derived nutrients for energy
generation to promote survival under conditions of starvation [2].
1.2. Induction of autophagy
In eukaryotic cells, autophagy is induced by starvation, hypoxia,
hormones, ER stress, redox stress, mitochondrial damage, pathogen-
associated molecular patterns or danger-associated molecular patterns
to degrade protein aggregates, oxidized lipids, damaged organelles,
and even intracellular pathogens [16–18]. In addition, autophagy pro-
motes cellular senescence [19], cell surface antigen presentation [20,21],
lipid metabolism [22], protects against genome instability [23–25] and
prevents necrosis [26]. Hence, autophagy plays a key role in preventing
disease. Dysregulation of autophagy is linked to cancer [27], neurodegen-
eration [28], metabolic syndrome [29], liver disease [30], autoimmune
diseases and infections [31].
1.3. Substrates of autophagy
Autophagy can be classiﬁed as nonselective or selective. As an adap-
tive response to nutrient starvation, nonselective autophagy promotes
bulk degradation of cytoplasm and organelles to provides amino acids
and lipid substrates for intermediarymetabolism [2]. Deﬁciencies in au-
tophagy result in maladaptation to starvation and poor survival due to
insufﬁcient amino acid production and protein synthesis. Autophagy
also occurs at low levels to mediate global turnover of cytoplasmic ma-
terials under nutrient-rich conditions [15]. Selective autophagy involves
degradation of organelles and protein aggregates. Selective autophagy
of protein aggregates and peroxisomes [32] involves ubiquitination of
target proteins, which are recognized by autophagy receptors, such as
p62 or Nbr1, which bind both ubiquitin and microtubule-associated
protein 1 light chain 3 (LC3) to deliver cargo to autophagosomes
[2,33,34]. Under speciﬁc conditions, selective autophagy of organelles
such as mitochondria (mitophagy) [35], ribosomes (ribophagy) [36],
endoplasmic reticulum (reticulophagy) [37], peroxisomes (pexophagy)
[38], and lipids (lipophagy) [39] occurs. For instance, mitophagy is
triggered by mitochondrial permeability transition pore opening and
loss of mitochondrial membrane potential [40].
1.4. Types of autophagy
Three types of autophagy have been deﬁned: macroautophagy,
microautophagy, and chaperone-mediated autophagy, each of which
promotes proteolytic degradation of intracellular cargo at the lysosome.
Macroautophagy transfers soluble cytoplasmicmaterials and organelles
to the lysosomes by utilizing the intermediate organelle called the
autophagosome, which is a product of an isolation membrane (termed
phagophore) enclosed within a small portion of the cytoplasm. The
autophagosome then fuses with the lysosome to form an autolysosome
and degrade the materials contained within [15] (Fig. 1). In micro-
autophagy, lysosomes directly engulf small pieces of the cytoplasm by
inward invagination of the lysosomal membrane [15]. In chaperone-
mediated autophagy, substrate proteins containing a KFERQ-like penta-
peptide sequence are ﬁrst bound with cytosolic Hsc70 then translocate
into the lysosomal lumen, where they are recognized by the lysosomal
membrane receptor lysosomal-associated membrane protein 2A,resulting in their unfolding and degradation [41]. Bothmacroautophagy
and microautophagy are able to consume large structures through
selective or nonselective mechanisms. The degradation products of all
three types of autophagy can be used for new protein synthesis, energy
production or gluconeogenesis. Among these, macroautophagy is the
predominant form and the most extensively studied [42]. This review
will focus on the role of macroautophagy (autophagy hereafter) in
cardiovascular diseases.
1.5. Process of autophagy
Theﬁrst Atg genewas identiﬁed in 1997 [43]. Genetic deletion of Atg
genes revealed the critical roles of autophagy in physiological adapta-
tion to stress and also a connection between defective autophagy and
various diseases. Atg proteins are comprised of four major functional
groups: (1) the Atg1/unc-51-like kinase (ULK) complex (Atg1/ULK1–
Atg13–Atg17) that responds to upstream signals; (2) the Beclin 1/
class III phosphatidylinositol 3-kinase (PI3K) complex (Atg6/Beclin1,
Atg14, Vps34/PI3KC3, and Vps15) that mediates vesicle nucleation
[44]; (3) two ubiquitin-like protein (Atg12 and Atg8/LC3) conjugation
systems that mediate vesicle expansion; (4) Atg9 and its cycling system
which provide lipids to the isolation membrane. These Atg-composed
protein complexes coordinate the formation of autophagosomes. The
Atg1/ULK1 complex (Atg1 in yeast and ULK1 in mammals) is an initial
regulator of autophagosome formation [34]. Under nutrient-rich condi-
tions, ULK1 is bound by mammalian target of rapamycin (mTOR) com-
plex 1(mTORC1), which phosphorylates ULK1 and inhibits autophagy
initiation. Whereas in starvation, mTORC1 dissociates from the ULK1
complex, releasing it to trigger autophagosome nucleation and elonga-
tion. In addition, ULK1 inhibits the kinase activity of mTORC1 through
binding with raptor to induce its phosphorylation [45]. Adenosine
monophosphate–activated protein kinase (AMPK) mediates the up-
stream signaling ofmTORC1which controls the cellular energy–sensing
pathway [34]. In response to high concentrations of AMP and its effects
on energy depletion, AMPK is activated,which, in turn, inhibitsmTORC1
and promotes autophagy [2]. Autophagy induction promotes ULK1
complex activation, which phosphorylates Beclin-1 on Ser14, thereby
enhancing the activity of Beclin1-Atg14-Vps34-Vps15 class III PI3K
core complexes to promote autophagosome nucleation [46]. Addition-
ally, under nutrient-rich conditions, Bcl-2 binds with the BH3 domain
of Beclin 1 and inhibits autophagy. The phosphorylation of Bcl-2 and
Beclin 1 disrupts this interaction and releases Beclin 1 [47].When nutri-
ents are abundant, Atg9 shuttles between the Golgi and endosomes. In
starvation, Atg9 distributes to endosomal compartments to supply a
membrane source for forming autophagosomes. Recent ﬁndings sug-
gest Atg9 plays an essential role in regulating oxidative stress-induced
JNK activation and autophagy through interaction with tumor necrosis
factor receptor-associated factor 6 [48–50]. Two ubiquitin-likemolecules,
Atg12 and Atg8 (called LC3 in mammals), are involved in expansion of
autophagosome membranes. Atg12 is ﬁrst activated by Atg7 which acts
like an E1 ubiquitin activating enzyme in an ATP-dependent manner.
Atg12 is then covalently linked to Atg5 by Atg10, an E2-like ubiquitin
carrier protein. Conjugated Atg5–Atg12 complexes bind Atg16L1 to
form pre-autophagosomal structures that induce a curvature into the
growing phagophore through asymmetric recruitment of processed
LC3B-II. LC3B is proteolytically cleaved by protease Atg4 to generate
LC3B-I. The carboxy terminal glycine exposed by Atg4-dependent cleav-
age is activated by the E1-like Atg7 and then transferred to Atg3. As a re-
sult, phosphatidylethanolamine is conjugated to the carboxyl glycine to
generate LC3B-II. Both Atg5–Atg12 and LC3B-II contribute recruitment
and integration of LC3B-II into the growing phagophore. The synthesis
and processing of LC3 are commonly used to monitor the progress of au-
tophagy because LC3-II remains on mature autophagosomes until after
fusion with lysosomes to generate autolysosomes. The contents are
then degraded by proteases, lipases, nucleases, and glycosidases, and
the breakdown products such as amino acids, lipids, nucleosides, and
Fig. 1. Intracellular pathways regulating macroautophagy.Macroautophagy transfers soluble cytoplasmic materials and organelles to the lysosomes by utilizing the intermediate or-
ganelle called the autophagosome, which is a product of an isolation membrane (termed phagophore) enclosed within a small portion of the cytoplasm. The autophagosome then
fuses with the lysosome to form an autolysosome and degrades the materials contained within. Autophagy is orchestrated by the Atg-composed protein complexes. Starvation or
AMPK activation inhibitsmTOR, leading to the release and activation of theULK1 complex (ULK1/Atg7/Atg13),which stimulates phagophore formation, and activates the Beclin1 complex
(Beclin1/Class III PI3K/Vps34/Vps15/Atg14). The Beclin1 complex promotes phagophore nucleation and elongation. Two ubiquitin-like molecules, Atg12 and Atg8 (called LC3 in mam-
mals), are involved in expansion of autophagosomemembranes. Conjugated Atg5–Atg12 complexes bind Atg16L1 to form pre-autophagosomal structures which induce the recruitment
of processed LC3-II. LC3-II remains on mature autophagosomes until after fusion with lysosomes to generate autolysosomes. The contents are then degraded by proteases, lipases, nucle-
ases, and glycosidases, and the breakdown products such as amino acids, lipids, nucleosides, and carbohydrates are released into the cytosol for synthetic and metabolic pathways. PE:
phosphatidylethanolamine.
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pathways [2] (Fig. 1).
1.6. Autophagic ﬂux measurement
Because the accumulation of autophagosomes may indicate autoph-
agy induction or impairment of autophagolysosomal maturation, au-
tophagic ﬂux assays are necessary to distinguish between autophagy
induction and a block in downstream steps [51]. Several of these assays
are discussed here. (1) LC3 turnover assay: based on the observation
that LC3-II is degraded in autolysosomes, LC3 turnover is one principal
method currently used to measure autophagic ﬂux. Inhibition of
autophagosome-lysosome fusion and thereafter protein degradation
by lysosomotropic reagents or lysosomal proteases inhibitors will result
in the accumulation of LC3-II, and the elevated levels of LC3-II indicate
that autophagic ﬂux is increased [52]. (2) Degradation of LC3 and its
substrates: LC3-II increases transiently upon autophagy induction, and
deceases during prolonged autophagy activation. Thus the amount of
total cellular LC3 and its substrate p62, quantiﬁed by immunoblot anal-
ysis or ﬂow cytometry, inversely correlates with autophagic ﬂux [53].
(3) Delivery of mRFP-GFP-LC3 to the lysosome: based on the concept
that the low pH inside the lysosome quenches the ﬂuorescent signal
of GFP, but not RFP. Therefore, an mRFP-GFP-LC3 tandem construct
labels autophagosomes with yellow and autolysosomes with red. The
increase of both yellow and red punctae indicates increased autophagic
ﬂux. Notably, each of these three methods has its own limitations. For
example, autophagic ﬂux can be detected even under basal conditions,
LC3 and p62 can be transcriptionally regulated during autophagy, and
sometimes autolysosomes are observed as yellow due to different acid-
iﬁcation and degradation capacities of the lysosome. Given thelimitations of the individual assays discussed above, a combination of
thesemethodswould provide themost precise prediction of autophagic
ﬂux in different cell types and experimental contexts [51].
2. Autophagy and cardiovascular diseases
Autophagy plays dual roles in cardiovascular diseases through
adaptive or maladaptive regulation. Physiological autophagy serves as
a protective mechanism to maintain normal cardiovascular function.
However, impaired autophagy contributes to disease development. A
better understanding of the function of autophagy in the cardiovascular
system could provide new therapeutic avenues for disease prevention
or control. As a consequence, the role of autophagy in the cardiovascular
system is currently under intense investigation.
2.1. Autophagy in atherosclerosis and cardiac ischemia
2.1.1. Autophagy in atherosclerosis
The discovery of autophagy-like ultrastructural features such as
vacuolization and formation of myelin ﬁgures by transmission electron
microscopy and expression of the autophagy marker LC3-II by western
blot analysis of human carotid plaques reveals that autophagy is one
major component in the process of atherosclerosis [54]. It is well
established that inﬂammation, hypoxia, oxidized lipoprotein, ER stress
and ROS are all involved in atherogenesis. In vitro studies have demon-
strated that these factors present in atherosclerotic plaques could also
serve as the triggers of autophagy [3–5]. Notably, autophagy in athero-
sclerotic plaques could be either beneﬁcial or detrimental. On one hand,
basal autophagy promotes plaque cell survival by successful degrada-
tion of damaged intracellular components, and thus protects cells
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mitochondria by autophagosomes limits the release of cytochrome C
into the cytosol and protects cells from apoptosis [55]. Autophagy is
induced in endothelial cells (ECs) or smooth muscle cells (SMCs) in
response to oxidized lipoprotein or lipid peroxidation products to
promote cell survival [5]. Autophagy also may mediate some anti-
inﬂammatory effects of resveratrol in EC [56]. Another study shows
upregulation of autophagy attenuates 7-ketocholesterol (a major com-
ponent of oxidized lipoproteins)-induced cell death in SMCs [57]. To-
gether these ﬁndings indicate that autophagy might be protective in
atherogenesis. Indeed, recent studies suggest autophagy favors plaque
stabilization by regulating lipid metabolism. Autophagy delivers lipid
droplets to lysosomes, where they are hydrolyzed by lysosomal acid
lipase to generate free cholesterol for efﬂux. Therefore, macrophage
foam cell cholesterol efﬂux is mediated by autophagy [58]. Wild-type
p53-induced phosphatase 1 (Wip1) is considered to control autophagy-
dependent macrophage cholesterol efﬂux [59]. Autophagy in macro-
phages is also protective in that disruption of autophagy in macrophages
in advanced plaques increases apoptosis and oxidative stress, thus
worsening efferocytosis and promoting plaque necrosis [60]. Loss of
macrophage autophagy increases plaque formation in part through
inﬂammasome hyperactivation and increased cholesterol crystal for-
mation, suggesting that intact autophagy suppresses the inﬂammasome,
which is essential in atheroprotection [61]. As a consequence, successful
autophagy could stabilize the atherosclerotic plaques and reduce adverse
vascular events [3,62].
On the other hand, excessive autophagy in SMCs or ECs may cause
cell death. SMC death destabilizes plaques due to the decreased synthe-
sis of collagenwhich results in a thinnerﬁbrous cap. Autophagymediat-
ed EC death is also the result of sustained ER stress in the atherosclerotic
lesion [4]. EC death may be detrimental by promoting thrombosis and
clinical events. However, macrophage death is considered a promising
approach for plaque stabilization [63]. Recent evidence suggests that
phagocytosis of macrophages dying through autophagy results in
inﬂammasome activation and inﬂammatory factor release [64]. The
above ﬁndings suggest that appropriate manipulation of autophagy
would foster its beneﬁcial effects in stabilizing the plaque by promoting
cell survival and reducing cell death.
2.1.2. Autophagy in cardiac ischemia/reperfusion
The direct effect of atherosclerosis is cardiac ischemia, and autophagy
activation in response to myocardial ischemia was documented 30 years
ago [7]. Hypoxia triggers signiﬁcant formation of autophagosomes
adjacent to swollen and fragmented mitochondria [7], suggesting there
may be interaction between autophagy and mitochondria during cardiac
ischemia. The ﬁndings that autophagy inhibitors promoted cardiac
myocyte death under glucose starvation suggested that autophagy
could be protective by replenishing depleted energy stores and removing
the toxic dysfunctional organelles. Going further, this study indicates that
AMPKmay participate in ischemia-induced autophagy that promotes cell
survival by eliminating dysfunctional mitochondria, which would other-
wise become a source of ROS and pro-apoptotic mediators [8].
A second wave of autophagy activation is triggered by reoxygena-
tion following ischemia.More autophagosomes are detected after ische-
mia/reperfusion as compared to hypoxia alone [7]. Autophagy could be
either adaptive or maladaptive in the context of ischemia/reperfusion
injury. Some studies suggest autophagic ﬂux is impaired during ische-
mia/reperfusion at the level of autophagosome formation and lysosome
degradation. In addition, impaired autophagosome clearance is associ-
ated with increased ROS and mitochondrial permeabilization, resulting
in cell death. This process is accompanied byROS-mediatedBeclin-1 up-
regulation and a decline in lysosome-associated membrane protein-2
and impaired autophagosome processing [65]. In contrast, other studies
show that overexpression of Beclin1 enhances autophagic ﬂux and pro-
tects cardiac cells from ischemia/reperfusion injury [66]. Consistent
with this result, Beclin 1+/− mice manifested attenuated autophagy,with less infarction and suppressed apoptosis [8]. Additionally, new sig-
naling involving BCL-2/adenovirus E1B 19-kDa interacting protein 3
(BNIP3) is a recently identiﬁed player in ischemia/reperfusion injury. As
a downstream target of hypoxia-inducible factor 1α, BNIP3 permeabilizes
cardiac mitochondria and promotes mitochondrial ﬁssion, causing
mitochondrial dysfunction and cardiomyocyte death during ischemia/
reperfusion injury. This process is related to autophagosome formation.
Forced expression of BNIP3 stimulates autophagy in cardiac myocytes
[67]. Autophagy serves as a protective mechanism in the setting of
BNIP3 expression in cardiac myocytes, as inhibition of autophagy in-
creases BNIP3-induced cardiomyocyte death by preventing removal of
damaged mitochondria [67]. Conversely, BNIP3 expression appears to
trigger autophagy and leads to a decline in lysosome abundance in car-
diacmyocytes. The resultant autophagosome accumulation prevents its
pro-survival role and triggers cardiomyocyte death [37].
Another important signaling protein in ischemia/reperfusion is gly-
cogen synthase kinase-3β (GSK-3β), which regulates autophagy during
prolonged ischemia in a time-dependent manner. In the initial phase of
ischemia, activation of GSK-3β stimulates autophagy, whereas during
subsequent reperfusion, inactivation of GSK-3β inhibits autophagy.
Such time-dependent regulation of endogenous GSK-3β adapts the car-
diacmyocyte to ischemia andprotects against reperfusion injury [68]. In
another pathway, ischemia-induced autophagy activation is dependent
on AMPK activation. In contrast, reperfusion-augmented autophagy is
dependent on Beclin1 instead of AMPK. Collectively, these results indi-
cate the distinct roles of autophagy during ischemia and reperfusion.
Autophagy may play an adaptive role during ischemia and a maladap-
tive role during reperfusion [8]. Thus, precise control of GSK-3β or
AMPK at different stages of ischemia/reperfusion would provide a
novel strategy to enhance survival under ischemic conditions and pro-
tect against cardiac myocyte death from reperfusion injury.
3. Autophagy in cardiomyopathy
Cardiomyopathy is classiﬁed as dilated, hypertrophic or restrictive
cardiomyopathy. Lamin A/C gene (LMNA) mutation-related dilated
cardiomyopathy is characterized by left ventricular enlargement and
decreased systolic function accompanied by arrhythmias and other
systemic diseases. Defective autophagy is one major feature in LMNA
cardiomyopathy, which could be caused by overexpression of dual
speciﬁcity phosphatase 4 in the heart and upregulated AKT-mTOR
signaling. Pharmacological interventions improve cardiac function,
which is correlated with enhanced autophagy [9–11]. A recent ﬁnding
is that mammalian target of rapamycin complex 1 mediates LMNA
deﬁciency-induced dilated cardiomyopathy. Elevated mTORC1 signal-
ing impairs autophagy, and mTORC1 inhibition with rapalogs extends
survival in the LMNA deﬁcient mice through restoration of autophagic
ﬂux and improved cardiac function [69]. The desmin-related cardiomy-
opathy (DRC) characterized by accumulation of misfolded proteins is
triggered by a missense mutation in the alphaB-crystallin (CryAB)
gene. Autophagy is considered an adaptive response in this proteotoxic
formof cardiomyopathy,which is evidencedby accelerated heart failure
and early mortality in DRCmice with genetic ablation of beclin1, a gene
required for autophagy [70]. In addition, transgenic overexpression of
the mutant desmin or CryAB (R120G) in mice in vivo as well as in vitro
upregulates p62mRNAandprotein levelswhich protects cardiomyocytes
from misfolded protein induced cell injury and death by maintaining re-
sponsive autophagosome formation and autophagy [71]. Atg7 induces
basal autophagy. Sustained Atg7 expression rescues impaired autophagy
in the CryAB (R120G) hearts with decreased cardiac hypertrophy and
prolonged survival, suggesting autophagy activation would be a viable
therapeutic strategy for ameliorating desmin-related cardiomyopathy
[12,72]. Dilated cardiomyopathy is linked with suppressed mitophagy,
which is the result of deﬁcient mitofusin-2. Ablation of mitofusin-2
prevented the translocation of Parkin to the mitochondria and
Parkin-mediated ubiquitination [73]. The proapoptotic kinase Mst1
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with Bcl-2 and/or Bcl-xL, and inhibits the phosphatidylinositide 3-
kinase activity of the Atg14L-Beclin1-Vps34 complex, thus suppressing
autophagy and providing a mechanism for the development of dilated
cardiomyopathy in man [74]. Very recently, the cardioprotective effects
of macrophage migration inhibitory factor (MIF) against doxorubicin-
induced cardiomyopathy has been recognized to function through
augmented autophagy [75]. Knockdown of myeloid cell leukemia-1
(MCL-1), an anti-apoptotic BCL-2 protein, in the adult heart led to
rapid development of cardiomyopathy and death,whichwas associated
with impaired induction of autophagy in the heart [76]. The above stud-
ies imply that defective autophagy contributes to cardiac dysfunction
and cardiomyopathy development; therefore, pharmacologic interven-
tions to augment autophagy might improve cardiac function and ame-
liorate cardiomyopathy.
In contrast, autophagy may promote cardiomyopathy. For instance,
histone deacetylases (HDACs) regulate cardiac plasticity. HDAC activity
is required for stress-induced cardiomyocyte autophagy which is linked
to load-induced cardiac hypertrophy. HDAC inhibitors have antihyper-
trophic effects due to the unique action of inhibiting augmented autoph-
agic ﬂux [77]. Diabetic cardiomyopathy, ﬁrst introduced by Rubler in
1972 [78], has been deﬁned as ventricular dysfunction that occurs
independently of coronary artery disease and hypertension. Changes in
myocardial structure, Ca2+ signaling andmetabolismhave been implicat-
ed in the pathogenesis of diabetic cardiomyopathy. Recently, the essential
role of autophagy in diabetic cardiomyopathy has been investigated in-
tensively. Diabetes induces cardiomyocyte apoptosis and suppresses car-
diac autophagy,which is linkedwith diabetic cardiomyopathy. Activation
of AMPK by metformin restores cardiac autophagy and prevents cardio-
myopathy presumably through disruption of Beclin1-Bcl-2 complex and
protects against cardiac apoptosis [79,80]. Interestingly, deﬁciency in au-
tophagy protects cardiac function in type1diabetes throughupregulation
of Rab9 regulated alternative autophagy and mitophagy [81]. Another
study shows that cardiac hypertrophy and dysfunction in type-2 diabetes
is dependent on saturated fatty acid and sphingolipid synthesis. In partic-
ular, ceramide synthase-5 is involved in lipid-induced autophagy and
lipotoxic cardiomyopathy [82]. Due to the important effects of autophagy
in metabolic disease-induced cardiomyopathy, autophagy could serve as
a biomarker for cardiac dysfunction and cardiomyopathy in diabetes.
4. Autophagy in heart failure
To date, heart failure remains one of the leading causes of death in
the United States. An estimated 5 million Americans have heart failure
with a mortality rate of approximately 50% in 5 years [83]. Heart failure
is a progressive disease characterized by adverse ventricular remodel-
ing which involves changes in the balance between cardiomyocyte
protein synthesis and degradation. It is recognized that the autophagy–
lysosome pathway is a housekeeper in cardiomyocytes under physiolog-
ical conditions. However, the role of autophagy in heart failure is contro-
versial. For instance, autophagy may antagonize ventricular hypertrophy
by increasing protein degradation and decreasing tissuemass. As a result,
autophagy may be an adaptive response to heart failure. In the mouse
heart, autophagy induced by sustained expression of Atg7 ameliorates
ventricular dysfunction, decreases cardiac hypertrophy, and prolongs
survival. These ﬁndings suggest that activation of autophagy may be a
viable therapeutic strategy for improving cardiac performance
under proteotoxic conditions [12]. However, the efﬁciency of protective
autophagy declines with age, leading to abnormal intracellular protein
aggregates, which result in enhanced oxidative stress, decreased ATP
production, and cell death. Oxidative stress sensitizes the heart to the
renin-angiotensin-aldosterone system, inducing autophagic type-II
programmed cell death and increasing the propensity for adverse cardi-
ac remodeling, diastolic dysfunction and heart failure [84]. Angiotensin
II (AngII) increases mitochondrial ROS in cardiomyocytes, concomitant
with increased autophagy in hearts of angiotensin II-treated mice [47].AngII type I (AT1) receptor mediates autophagosome formation in re-
sponse to AngII stimulation. This response, however, is blocked by co-
expression of the AngII type 2 (AT2) receptor in neonatal cardiomyocytes
[85]. A robust autophagic response in cardiomyocytes is elicited by
pressure overload stress, this response is maladaptive, as excessive au-
tophagy in load-induced heart failure leads to autophagic cell death,
loss of cardiomyocytes, andmay contribute to theworsening of heart fail-
ure. Mechanical unloadingwith a left ventricular assist device attenuated
autophagy, reduced energy demand and improved function of the failing
human heart [86].
Autophagy in cardiomyocytes is affected by a variety of stimuli, such
as lipid and glucose. High fat diet (HFD) disrupts autophagosome
maturation at the step of autophagosomes fusion with lysosomes. This
impaired autophagic ﬂux is associated with increased apoptosis, mito-
chondrial injury, intracellular Ca2+ dysregulation and cardiac dysfunc-
tion [13]. Akt2 was considered to play a predominant role in HFD-
induced cardiac hypertrophy and contractile dysfunction. Akt2 ablation
has cardioprotective effect in that it rescues HFD-induced disruption of
the autophagosome maturation process and facilitated the transition
from autophagosomes to autophagolysosomes [13]. Conversely, com-
pared with normal glucose (5.5 mM), high glucose (17 or 30 mM)
decreases autophagic ﬂux in cardiomyocytes. In addition, high glucose-
induced cardiomyocyte death is attenuated by suppression of autophagy
by 3-methyladenine or silencing of the Becn1 or Atg7 gene. In contrast,
augmentation of autophagy with rapamycin or overexpression of Becn1
or Atg7 predisposes cardiomyocytes to high glucose toxicity. These
results indicate that reduced autophagic ﬂux is an adaptive response
that serves to limit high glucose-induced cardiac toxicity [87]. Autophagy
also protects the heart from intermittent hypoxia-induced systolic
dysfunction by maintaining contractile function [88]. miR-212 and miR-
132, two important miRNA involved in cardiac hypertrophy, are upregu-
lated in hypertrophic cardiomyocytes. Overexpression of miR-212 and
miR-132 leads to impaired autophagic response to starvation, hypertro-
phy and heart failure. MiR-212/132 deletion protects mice from
pressure-overload-induced heart failure [89]. The cytokine MIF elicits
cardioprotective effects through AMPK activation. As an illustration of
its importance, MIF deﬁciency exacerbates left-ventricular dysfunction
following starvation. This process is mediated by interrupted starvation-
induced autophagic vacuole formation and exacerbated starvation-
induced cell death. These results indicate that MIF preserves cardiac con-
tractile function under starvation by regulating autophagy [90]. A recent
study showed thatmitochondrial homeostasis and autophagy are depen-
dent on MCL-1 which is based on the observation that cardiomyocyte-
speciﬁc MCL-1 knockout mice developed rapid cardiomyopathy and
heart failure [76]. Finally, the regulatory associated protein of mTOR
(Raptor) is an mTOR binding partner that mediates mTOR signaling to
downstream targets. Ablation of raptor reduces myocardial mTORC1
activity, leading to heart failure, dilated cardiomyopathy and highmortal-
ity, which is associated with apoptosis and augmented autophagy in
cardiomyocytes [91]. In summary, autophagy, controlled by a variety of
factors, may antagonize ventricular hypertrophy and alleviate heart fail-
ure by increasing protein degradation and decreasing tissue mass. On
the other hand, excessive autophagy under certain conditions such as
pressure overload leads to cell death, and may contribute to the worsen-
ing of heart failure.
5. Autophagy in hypertension
Hypertension is classiﬁed as primary hypertension and secondary
hypertension. Primary hypertension accounts for 90–95% of cases with-
out obviousmedical cause. The remaining 5–10% of cases are secondary
effects of diseases in kidneys, arteries, heart or endocrine system. The
heart exhibits robust hypertrophic growth in response to hypertension,
which is regulated by autophagy. Essential cellular elements eliminated
by excessive autophagy may provoke cell death and contribute to
hypertension-related heart disease [92]. Excessive proliferation and
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(PASMCs) are features of pulmonary arterial hypertension. PASMC pro-
liferation facilitates vascular remodeling, leads to narrowed vascular
lumen and increased pulmonary vascular resistance, and eventually in-
creased pulmonary arterial pressure. Recently, chloroquine, a widely
used antimalarial and antirheumatoid drug, was shown to prevent the
development ofmonocrotaline-induced pulmonary hypertension by in-
hibition of autophagy.Monocrotaline-induced pulmonary hypertension
is characterized by increased expression of LC3B-II and reduced expres-
sion of p62 in muscularized small pulmonary arteries, which is accom-
panied by increased medial thickness and proliferation of PASMCs.
Chloroquine inhibited autophagy and restored p62 levels in the media
of small pulmonary arteries in vivo, and was associated with inhibition
of proliferation and induction of apoptosis in PASMCs in small pulmo-
nary arteries. The underlyingmechanismwas attributed to chloroquine
preventing acidiﬁcation of the lysosome and subsequent processing of
the autophagosome, thus preventing degradation of bonemorphogenetic
protein type II receptor (BMPR-II). The conserved intact BMPR-II signaling
along with impaired autophagy contributes to a pro-apoptotic, anti-
proliferative phenotype in PASMCs, indicating that autophagy is involved
in pulmonary hypertension [93]. In another model, sympathetic pre-
motor neurons that maintain vasomotor tone in the rostral ventrolateral
medulla (RVLM) play a pivotal role in neurogenic hypertension. Drugs
inhibiting autophagy in RVLM decreased hypertension in spontaneously
hypertensive rats, suggesting autophagy could be a therapeutic target in
the control of neurogenic hypertension [94]. Taken together, these stud-
ies suggest that autophagy promotes pulmonary hypertension and neu-
rogenic hypertension. Inhibition of autophagy could provide a new
therapeutic strategy in the management of hypertension.
6. Autophagy and oxidative stress in cardiovascular disease
Emerging evidence indicates oxidative stress plays an important role
in cardiovascular disease development. Dysregulation of autophagy ren-
ders cardiomyocytes more prone to ischemia-induced injury and cardiac
remodeling [95]. H2O2 signiﬁcantly increased both autophagosomes and
autolysosomes and, thus, autophagic ﬂux in cardiac myocytes. N-2-
mercaptopropionyl glycine (MTG), an antioxidant, attenuates autophagy
in the presence of H2O2 in vitro, as well as autophagic ﬂux in ischemia/
reperfusion-induced oxidative stress in vivo. The impaired autophagy
in vivo is accompanied by a decrease in the size of myocardial infarction.
Moreover, Beclin1+/− mice have reduced myocardial infarction after
ischemia/reperfusion, whereas MTG treatment results in no additional
reduction of infarct size. These results imply that autophagy mediates
myocardial injury by increasing the oxidative stress elicited by ische-
mia/reperfusion [14]. In cardiacmyocytes, ROS are also stimulated by glu-
cose deprivation. Inhibition of ROS disrupted autophagy induced by
glucose deprivation, emphasizing the important effects of oxidative stress
on the activation of autophagy in cardiac myocytes induced by energy
stress [96]. In the context of hypertension and diabetes, oxidative stress
sensitizes the heart to the renin-angiotensin-aldosterone system, induces
autophagic type-II programmed cell death, and leads to accelerated cardi-
ac remodeling and cardiac dysfunction. Adiponectin, an adipokine known
tomediate cardioprotective effects, demonstrates antioxidant potential to
attenuate autophagy induced by excessive ROS in cardiomyocytes by
inhibiting H2O2-induced AMPK/mTOR signaling [84]. Mitophagy plays
an important role inmitochondrial quality control and cellular homeosta-
sis through selective degradation of dysfunctional mitochondria. Dys-
functional mitochondria produce excess ROS which triggers oxidative
stress. In the diabetic heart, mitophagy was decreased as evidenced by
decreased Pink and Parkin, accompanied by decreased Lamp1 levels. As
expected, impairedmitophagy in the diabetic heart increased ROS gener-
ation and oxidative protein damage, and the antioxidant enzymeMnSOD
was also decreased. Notably, Beclin-1 deﬁciency restoredmitophagy, and
the MnSOD level was partially restored, and thereafter, ROS generation
and oxidative protein damage was attenuated. These results indicatethat inhibition of autophagy improves mitophagy and protects the heart
from diabetes-induced oxidative injury [81]. Furthermore, autophagy
also mediates inﬂammatory responses in cardiac myocytes. For instance,
monocyte chemotactic protein-1 (MCP-1) promotes the development of
heart failure by inducing oxidative stress. MCP-1-induced protein
(MCPIP) mediates the downstream effects of oxidative stress, including
ER stress, autophagy and cell death, and these processes are inhibited
by inhibitors of oxidative stress. In addition, inhibitors of ER stress inhibit
autophagy and cell death. These ﬁndings indicate that the elevatedMCP-
1 levels associated with chronic inﬂammation may contribute to the de-
velopment of heart failure through oxidative stress-induced ER stress
and autophagy [97].
Conversely, autophagy serves to protect against disease develop-
ment bymediating protein quality control. Antimycin A (AMA) induces
mitochondrial stress and increases mitochondrial superoxide genera-
tion, as well as augments nuclear DNA oxidation and cell death in
cardiomyocytes. Upregulated autophagy by rapamycin promotes mito-
chondrial clearance and protects cardiomyocytes from the AMA-
induced cell injury. In addition, the accumulation of ubiquitinylated
proteins induced by AMA is suppressed by autophagy. Hence, autopha-
gy induction could become a potential therapeutic strategy against oxi-
dative stress-mediated injury in cardiomyocytes [98]. Autophagy also
plays a protective role in AngII induced oxidative stress. Atg5+/−mice
have impaired autophagy and increased production of ROS, which acti-
vates nuclear factor κB (NF-κB) in macrophages and increases cardiac
inﬂammation. As a consequence, Atg5+/−mice are associated with in-
creased cardiac ﬁbrosis. Thus, intact autophagy signaling protects the
heart from hypertension-induced inﬂammation and cardiac injury
[99]. In addition to mitochondria, ROS production in cardiomyocytes
during glucose deprivation is dependent on NADPH oxidase-4 ex-
pressed in the ER. ROS produced in the ER induce autophagy in the
cardiomyocytes and promote survival in response to energy stress.
These effects aremediated by the protein kinase RNA-activated-like en-
doplasmic reticulum kinase/eukaryotic initiation factor-2α/activating
transcription factor-4 pathway [100]. To summarize, depending on the
pathologic environment, autophagy may mediate oxidative stress-
induced cell injury and cell death through autophagic type-II pro-
grammed cell death or protect against cell injury from ROS produced
by mitochondria or the ER.
7. Manipulation of cardiac autophagy
The transition of autophagy fromanadaptive phase to amaladaptive
phase plays a vital role in driving the development of cardiovascular dis-
ease. As described above, autophagy can have either beneﬁcial or detri-
mental effects in the cardiovascular system. Adaptive autophagy
promotes survival in response to hypoxia and oxidative stress by re-
moving damaged organelles as well as recycling macromolecules to
maintain energy levels and support protein synthesis. In contrast,
prolonged hypoxia and subsequent reperfusion result in maladaptive
autophagy which causes cell death through excessive self-digestion of
essential organelles andproteins or inducing apoptosis. Thus,manipula-
tion of autophagy may represent a potential therapeutic target to treat
or prevent development of heart disease. Lysosomal-associated mem-
brane protein 2 (Lamp-2) is a ubiquitous lysosomal membrane protein
required for the proper fusion of lysosomes with autophagosomes
[101]. Lamp-2 depletion results in the inhibition of cytoprotective au-
tophagy signaling secondary to the failure of fusion between lysosomes
and autophagosomeswhich is linked toDanon disease, characterized by
severe cardiomyopathy [102]. The failure of autolysosome fusion is a
hallmark of the maladaptive autophagy which results in the accumula-
tion of autophagic vacuoles and the autophagosome-associated pro-
teins LC3 and p62, coupled with increased apoptosis [103]. Autophagic
ﬂux assaysmay be used to determine the autophagic status in patholog-
ical conditions; however, the lack of suitable assays for measuring the
ongoing autophagic ﬂux in humans limits the feasibility of identifying
249Y. Mei et al. / Biochimica et Biophysica Acta 1852 (2015) 243–251the optimal window of autophagic activation to exploit the cardio-
protective effects of macroautophagy without disrupting cardiac ho-
meostatic mechanisms. A combination of measurement of circulating
LC3 levels in the blood and in vivo imaging of autophagy markers in
the heart would provide better information about disease progression
and generate corresponding therapeutic approaches. Indeed, animal
studies have yielded promising results. Upregulated autophagy has ben-
eﬁcial effects on cardiovascular diseasemanagement. In vivowork indi-
cates sustained expression of autophagy-related 7 in the CryAB (R120G)
hearts leads to decreased cardiac hypertrophy, ameliorated ventricular
dysfunction, and prolonged survival [12]. In addition, inhibition of
mTOR by everolimus limits infarct size and attenuates adverse left ven-
tricular remodeling after myocardial infarction in mice [8]. Moreover,
chronic AMPK activation by metformin prevents cardiomyopathy by
upregulating autophagy in diabetic mice [104]. Recently, Xu et al.
reported that rapamycin restored autophagy activity in the hearts of
cardiomyocyte-phosphatase and tensin homolog knockout mice, re-
versing hypertrophic cardiomyopathy [105]. In contrast, downregula-
tion of autophagy may also protect cardiac function. For instance,
histone deacetylase inhibitors attenuate cardiac hypertrophy and im-
prove cardiac function by suppressing autophagy [77]. In addition to
testing autophagy inhibitors or activators such as mTOR inhibitors and
AMPK activators, it is worthwhile to explore the effects of current med-
ications already used clinically such as β-blockers, Ca2+ channel
blockers, vasodilators and statins on autophagy, as well as safe dose
ranges to ensure their positive effects in cardiac autophagy and protect
cardiac function.
8. Conclusions
This review summarizes themost current ﬁndings on how autophagy
is executed and regulated, and how the integration or disruption of au-
tophagy pathways contributes to cardiovascular physiology and disease.
Deﬁning the mechanisms of autophagy pathways in different cell types
in the cardiovascular systemand the importance of autophagosomal deg-
radation of organelles such as endoplasmic reticulum and mitochondria
during oxidative stress has the potential to yield novel therapeutic
approaches for the treatment of cardiovascular diseases.
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